INDV vs. RYTM, ACAD, JANX, GERN, VERA, DYN, DCPH, ARVN, BHC, and PTCT
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include Rhythm Pharmaceuticals (RYTM), ACADIA Pharmaceuticals (ACAD), Janux Therapeutics (JANX), Geron (GERN), Vera Therapeutics (VERA), Dyne Therapeutics (DYN), Deciphera Pharmaceuticals (DCPH), Arvinas (ARVN), Bausch Health Companies (BHC), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Rhythm Pharmaceuticals (NASDAQ:RYTM) and Indivior (NASDAQ:INDV) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.
Rhythm Pharmaceuticals received 274 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 65.71% of users gave Rhythm Pharmaceuticals an outperform vote.
In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Indivior. MarketBeat recorded 5 mentions for Rhythm Pharmaceuticals and 0 mentions for Indivior. Indivior's average media sentiment score of 0.60 beat Rhythm Pharmaceuticals' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.
Rhythm Pharmaceuticals currently has a consensus target price of $54.33, indicating a potential upside of 39.46%. Indivior has a consensus target price of $36.00, indicating a potential upside of 110.65%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Indivior is more favorable than Rhythm Pharmaceuticals.
Indivior has a net margin of 0.44% compared to Indivior's net margin of -297.91%. Rhythm Pharmaceuticals' return on equity of 842.72% beat Indivior's return on equity.
Indivior has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
60.3% of Indivior shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Rhythm Pharmaceuticals has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Summary
Indivior beats Rhythm Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INDV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
